Metodologías de laboratorio para la determinación de la incidencia del Virus de la Inmunodeficiencia Humana (VIH)

Autores

Resumen

La determinación de la incidencia del Virus de la Inmunodeficiencia Humana (VIH) constituye uno de los principales objetivos en la vigilancia epidemiológica la infección por este virus. Con la implementación de una nueva metodología de laboratorio, que sustituye a sus predecesoras en términos de complejidad y costo, se ha abierto la oportunidad para que en un futuro cercano cualquier país pueda incorporar esta técnica como parte de los protocolos ya existentes de vigilancia, esto una vez que esta sea validada por el CDC con la colaboración de los países de la región. Además, la OMS recomienda introducir esta nueva metodología en un algoritmo de infección reciente para la clasificación final de los pacientes portadores del VIH, con el fin de obtener valores confiables de la incidencia de este virus en la población. El objetivo de esta investigación es revisar las metodologías existentes para determinar la incidencia del VIH y la importancia de su validación e implementación en los sistemas de vigilancia epidemiológica.

Palabras clave

Abstract

The incidence determination of HIV is one of the main objectives in the epidemiological surveillance of infection by this virus. With the implementation of a new laboratory methodology, which replaces its predecessors in terms of complexity and cost, the opportunity has been opened up so that in the near future any country can incorporate this technique as part of the existing surveillance protocols, this once it is validated by the CDC with the collaboration of the countries of the region. In addition, the WHO recommends introducing this new methodology in a recent infection algorithm (RITA) for the final classification of patients with HIV, in order to obtain reliable values of the incidence of this virus in the population. The objective of this research is to review existing methodologies to determine the incidence of HIV and the importance of its validation and implementation in epidemiological surveillance systems.

Key words

Texto completo

VER PDF

Referencias

Referencias
1. World Health Organization. (2016). Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations.
2, Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol 1995; 141: 166–172
3. Kassanjee, R., Pilcher, C.D., Keating, S., Facente, S.N, McKinney, E., Price, M.A., Welte, A. (2014). Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (London, England), 28(16), 2439.
4. Granade, T. C., Nguyen, S., Kuehl, D. S., & Parekh, B. S. (2013). Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS research and human retroviruses, 29(1), 61-67.
5. Technical Update on HIV Incidence Assays for Surveillance and Monitoring Purposes. UNAIDS/WHO, 2015.
6. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998, 280:42-48
7. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and -estimating incidence. AIDS Res Hum Retroviruses 2002, 18:295-307.
8. Young CL, Hu DJ, Byers R, et al. Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B’ or E infection in Thailand. AIDS Res Hum Retroviruse 2003, 19:481-486.
9. Karita E, Price M, Hunter E, Chomba E, Allen S, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 2007, 21:403-408.
10. Laeyendecker O, Oliver A, Astemborski J, Owen SM, Kirk G, et al. Improved precision of crosssectional HIV incidence testing using a multi-assay algorithm that includes BED and an avidity assay with modified assay cut-offs. Conference on Retroviruses and Opportunistic Infections. San Francisco. 2010, #935.
11. Wei X, Liu X, Dobbs T, Kuehl et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010, 26:1-11.
12. Sedia Bioscienses Corporation. (2016). SediaTM HIV-1 Lag-Avidity EIA: Single Well Avidity Enzyme Immunoassay for Detection of Recent HIV-1 Infection Using Serum of Plasma Only. Portland, Oregon, United States
13. Sedia Bioscienses Corporation. (2017). Asanté HIV Rapid Recency Assay: Rapid in vitro immunoassay for determining Recency of Human Immunodeficiency Virus (HIV-1) infections.
Portland, Oregon, United States